The rate for the second coprimary efficacy endpoint ( stroke or SE > 7 days ' postrandomization ) was 0.0253 versus 0.0200 ( risk difference 0.0053 [ 95 % CrI : -0.0190 to 0.0273 ] ) , achieving noninferiority .